116 related articles for article (PubMed ID: 34884681)
1. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor: A novel treatment option for nurse practitioners treating patients with psoriatic disease.
Young M; Roebuck HL
J Am Assoc Nurse Pract; 2016 Dec; 28(12):683-695. PubMed ID: 27869356
[TBL] [Abstract][Full Text] [Related]
2. Preclinical and clinical evidence for suppression of alcohol intake by apremilast.
Grigsby KB; Mangieri RA; Roberts AJ; Lopez MF; Firsick EJ; Townsley KG; Beneze A; Bess J; Eisenstein TK; Meissler JJ; Light JM; Miller J; Quello S; Shadan F; Skinner M; Aziz HC; Metten P; Morrisett RA; Crabbe JC; Roberto M; Becker HC; Mason BJ; Ozburn AR
J Clin Invest; 2023 Mar; 133(6):. PubMed ID: 36656645
[TBL] [Abstract][Full Text] [Related]
3.
Liadaki K; Zafiriou E; Giannoulis T; Alexouda S; Chaidaki K; Gidarokosta P; Roussaki-Schulze AV; Tsiogkas SG; Daponte A; Mamuris Z; Bogdanos DP; Moschonas NK; Sarafidou T
Genes (Basel); 2024 Mar; 15(3):. PubMed ID: 38540428
[TBL] [Abstract][Full Text] [Related]
4. Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases.
Schett G; Sloan VS; Stevens RM; Schafer P
Ther Adv Musculoskelet Dis; 2010 Oct; 2(5):271-8. PubMed ID: 22870453
[TBL] [Abstract][Full Text] [Related]
5. Apremilast Decreased Proinflammatory Cytokines and Subsequently Increased Inhibitory ones in Psoriasis: A Prospective Cohort Study.
Fukasawa T; Yoshizaki-Ogawa A; Enomoto A; Sato S; Yoshizaki A
Acta Derm Venereol; 2024 May; 104():adv37555. PubMed ID: 38738774
[No Abstract] [Full Text] [Related]
6. ME3183, a novel phosphodiesterase-4 inhibitor, exhibits potent anti-inflammatory effects and is well tolerated in a non-clinical study.
Kubota-Ishida N; Kaji C; Matsumoto S; Wakabayashi T; Matsuhira T; Okura I; Cho N; Isshiki S; Kumura K; Tabata Y
Eur J Pharmacol; 2024 Jan; 962():176202. PubMed ID: 37996010
[TBL] [Abstract][Full Text] [Related]
7. Update on the treatment of psoriasis and psoriatic arthritis - role of apremilast.
Forchhammer S; Ghoreschi K
Psoriasis (Auckl); 2015; 5():117-124. PubMed ID: 29387588
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Apremilast Gels in Mouse Model of Imiquimod-Induced Psoriasis Skin Inflammation.
Silva-Abreu M; Sosa L; Espinoza LC; Fábrega MJ; Rodríguez-Lagunas MJ; Mallandrich M; Calpena AC; Garduño-Ramírez ML; Rincón M
Pharmaceutics; 2023 Sep; 15(10):. PubMed ID: 37896163
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase-4 Inhibition in the Management of Psoriasis.
Crowley EL; Gooderham MJ
Pharmaceutics; 2023 Dec; 16(1):. PubMed ID: 38258034
[TBL] [Abstract][Full Text] [Related]
10. PDE4 inhibitors: potential protective effects in inflammation and vascular diseases.
Fan T; Wang W; Wang Y; Zeng M; Liu Y; Zhu S; Yang L
Front Pharmacol; 2024; 15():1407871. PubMed ID: 38915460
[TBL] [Abstract][Full Text] [Related]
11. Circulating Monocytes Are Predictive and Responsive in Moderate-to-Severe Plaque Psoriasis Subjects Treated with Apremilast.
Larson EL; DeMeo DP; Young AB; Margevicius S; Rutter J; Davies AL; Rohan CA; Korman NJ; Travers JB; McCormick TS; Cooper KD
J Invest Dermatol; 2024 Feb; ():. PubMed ID: 38431222
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 4-Ethoxy-6-chloro-5-azaindazoles as Novel PDE4 Inhibitors for the Treatment of Alcohol Use Disorder and Alcoholic Liver Diseases.
Zheng L; Aimaiti Z; Long L; Xia C; Wang W; Zhou ZZ
J Med Chem; 2024 Jan; 67(1):728-753. PubMed ID: 38156615
[TBL] [Abstract][Full Text] [Related]
13. Apremilast Microemulsion as Topical Therapy for Local Inflammation: Design, Characterization and Efficacy Evaluation.
Sarango-Granda P; Silva-Abreu M; Calpena AC; Halbaut L; Fábrega MJ; Rodríguez-Lagunas MJ; Díaz-Garrido N; Badia J; Espinoza LC
Pharmaceuticals (Basel); 2020 Dec; 13(12):. PubMed ID: 33371334
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab-Induced Rupioid Psoriasis Treated by Apremilast Without Interrupting the Ongoing Antineoplastic Treatment.
Ambrogio F; Rubino L; Laface C; Cazzato G; Foti C
Cureus; 2024 Feb; 16(2):e55249. PubMed ID: 38558625
[TBL] [Abstract][Full Text] [Related]
15. Otezla (Apremilast), an Oral PDE-4 Inhibitor, Receives FDA Approval for the Treatment of Patients with Active Psoriatic Arthritis and Plaque Psoriasis.
Fala L
Am Health Drug Benefits; 2015 Mar; 8(Spec Feature):105-10. PubMed ID: 26629274
[No Abstract] [Full Text] [Related]
16. Correction for: Apremilast ameliorates IL-1α-induced dysfunction in epidermal stem cells.
Jia Y; Chen X; Sun J
Aging (Albany NY); 2024 Mar; 16(6):5792-5794. PubMed ID: 38578657
[No Abstract] [Full Text] [Related]
17. Phosphodiesterase-4 Inhibition Reduces Cutaneous Inflammation and IL-1β Expression in a Psoriasiform Mouse Model but Does Not Inhibit Inflammasome Activation.
Meier-Schiesser B; Mellett M; Ramirez-Fort MK; Maul JT; Klug A; Winkelbeiner N; Fenini G; Schafer P; Contassot E; French LE
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884681
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
